PeptideStack
5.2kquestions
20kanswers
220users

Is there any published stability data for ecnoglutide at 2–8 °C?

Asked 13 Aug 2024Modified 21 months agoViewed 57k times
40

The case in front of me: ecnoglutide · 2–8 °C.

The claim is plausible, which is exactly why I want to check it.

I am able to read a paper if someone points me at one.

Has anyone verified this independently?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
ecnoglutide
ecnoglutide

A long-acting GLP-1 receptor agonist with a cAMP-biased signalling profile. A niche tag, mostly used for mechanism questions about biased agonism…

223 questions
shareeditfollowflag
PM
askedp_mkhize58k23813 Aug 2024
8What temperature, and for how long? Both are needed before anyone can say anything useful. – m_haraldsen 2 months ago
7Do you know the residual moisture? It predicts this better than any date does. – gunnar_isaksen 21 days ago
add a comment

3 Answers

Accepted answer first, then by votes
44

Accepted answer

Probably not at 2–8 °C specifically, because that is not where stability programmes take their readings. Accelerated work is conventionally run at 25 °C and 40 °C, with the refrigerated condition as the control, so 2–8 °C sits between or beyond the published points and what you will find is bracketing rather than a measurement. 2–8 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. Whatever you find, check what was measured before you use it: a paper reporting purity at 2–8 °C has not measured content, and the two fail at different rates for different reasons.

Start with the sequence, because which pathways are available depends on which residues are present.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Reported and extrapolated stability by condition

StateConditionUsable windowBasis
Lyophilised solid−20 °C, sealed, dry24–36 monthsSupplier guidance
Lyophilised solid2–8 °C, sealed12–24 monthsSupplier guidance
Lyophilised solid25 °C, sealed4–8 weeksExtrapolated (Arrhenius)
Lyophilised solid40 °C, sealed1–2 weeksExtrapolated
Solution, preserved2–8 °C28 daysUSP microbiological convention
Solution, preserved25 °C3–7 daysExtrapolated
Solution, unpreserved2–8 °C24 hoursUSP microbiological convention

Windows for the solid state are chemical; windows for solution are microbiological and usually shorter than the chemical limit.

Mechanically, hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
DL
answered · acceptedDr_Otto_Lindqvist72k5816 Oct 2024
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
40

Answering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Cold, dry, dark, still. Those four words cover most of the mitigation.

edited 2 Nov 2024 by marta_okonkwo — added the method parameters

shareimprove this answerflag
MO
answeredmarta_okonkwo190k2585 Oct 2024
18

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

Sequence decides which pathways are even available. Check the residues.

shareimprove this answerflag
IB
answeredines_brandt113k25713 Sept 2024
4Worth adding that residual moisture predicts this better than any printed date. – sinead_gaffney 2 months ago
3Adding a vote because this deserves more of them. – ines_brandt 2 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.